The Motley Fool

Is the Ramsay Health Care Limited (ASX:RHC) share price in the buy zone?

Although the Ramsay Health Care Limited (ASX: RHC) share price finished the day slightly higher on Thursday, at one stage the private hospital operator’s shares tumbled to a multi-year low of $53.01.

At that point Ramsay Health Care’s shares were down a remarkable 30% since peaking at $76.18 in August of last year.

Is Ramsay Health Care cheap enough to buy now?

While Ramsay Health Care’s shares are becoming a lot more attractive now after this sizeable decline, I wouldn’t be a buyer just yet.

After all, as I mentioned at the start of the week, Goldman Sachs initiated coverage on the private hospital operator with a sell rating and $49.00 price target. Which could mean it still has further to fall.

This bearish call was made on the belief that Ramsay Health Care’s shares are overvalued and that it faces challenging industry dynamics from rising healthcare costs and the decline in private health insurance (PHI) participation.

So although its shares hit a multi-year low today, they would have to fall a lot further before I would be willing to invest.

What is a good buy price?

I would be interested in picking up shares in Ramsay Health Care if they fell to $45.00 or below. At this level I think they provide a decent risk/reward, especially for a long-term investment.

Based on Goldman’s forecast for earnings per share of $2.86 in FY 2019, Ramsay Health Care’s shares would be trading on a forward price to earnings ratio of just under 16x if they came down to the $45.00 mark. I think this earnings multiple is more befitting for its current growth profile.

But until that happens, I plan to stay away from the company’s shares and focus on other healthcare options such as CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH).

Alternatively, this ASX small cap healthcare share is up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here’s the best part: we think there’s one ASX stock that’s uniquely positioned to profit immensely from this explosive new industry… taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more